Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Could be...........but, I keep wondering about this announcement language......$ONCS PR:" OncoSec Announces $30 Million USD Strategic Investment at a Premium to Market by China Grand Pharmaceutical and Healthcare Holdings (CGP) in Connection with Exclusive License to TAVO™ in Greater China and 35 Other Asian Countries." ......"in Greater China and 35 Other Asian Countries." Doesn't that leave the rest of the world up in the air? I keep feeling like I'm missing some critical detail
here. What about the rest of the world.....that's where I live?
Oxytoma Hargrovei
Jeff, you'll recall that back on May 29th, ONCS issued a press release announcing the joint venture with Australia's Emerge Health to treat "last chance" melanoma patients. This was to begin in the 4th Qtr.
I imagine ONCS is in the logistics, set-up stage, to be ready to start treatment of those Australia patients. I doubt that the recent "up trend" has anything to do with the ONCS/Emerge Health venture.
However, as stated in the PR......"This collaboration will allow OncoSec to begin generating revenue, potentially as early as the fourth quarter of 2019. The ability to begin this process in Australia with TAVO sets OncoSec apart from other clinical-stage companies developing therapies for the treatment of refractory metastatic melanoma. TAVO will be the only drug available under the SAS program for melanoma patients who have failed checkpoint inhibitor or targeted therapy."
Anyhow, I'm looking forward to some indication of how this will be working out (patient load, potential revenue etc.) but, I doubt we'll hear anything from ONCS on this until after the beginning of 2020. Nice expectation on the horizon though!
Oxytoma Hargrovei
Jeff, really good article that focuses on how the highly regarded Dana-Faber Cancer Institute views ONCS' "tavo" application coupled with anti--PD1 inhibitors. Nice explanation of how that combination can disturb the micro-environment cancer cells thrive in and can led to striking immune responses that often lead to favorable outcomes like halting disease progression and total disease cure. Our own Board's resident "Professor Hschlauch" has often spoken of the novel medicinal "DISTURBANCE" TAVO represents for the immunotherapy community. I miss hearing from the "Professor" but, now with classes back in session, perhaps he will be making some guest appearances soon! I look forward to that!
Oxytoma Hargrovei
"hschlauch"
Great find.......perhaps a just a natural reaction to what may very well be a "profound development" for Oncosec; but, anytime I see Dr. Robert H. Pierce and Oncosec being mentioned together, I always see a "big green light flashing" and feel like good things are in the works. Thanks for sharing this development with the board!
Always good to see an informative news item from you!
"Oxytoma Hargrovei"
"hschlauch!"
You are a "visionary" and a main "spark" for this discussion board......you are imaginative and can grasp
how Merck, BMS, and other similar "Big Dogs" may be seeing ONCS as part of their future! Me, I'm a simple chariot driver, who is now thinking about getting a new, larger chariot.....one better able to haul more $$$$$$$!
You have vision and the rest of us have to wear bifocals!
THANKS AGAIN!
Oxytoma Hargrovei
Thanks for the Monday morning perspective on a significant ONCS highlight.........for some reason, this lyric jumped into my head..........will the chariot be loaded with $$$$$$$$$$$$$$$!?!?
Good news, the chariot's coming, Good news, the chariot's coming,
Good news, oh, the chariot's coming
Good news, the chariot's coming,
Yeah, I don't want to be (left) behind.
Nice way to start a week!
Always good to see your "research-based" comments!
Oxytoma Hargrovei
"akhsv777"
I'm right there with you regarding the value of "hschlaugh's" perspective on current ONCS trial(s).
Like the "Lone Ranger," hschlaugh has a knack for arriving just in the nick of time to save the day! He's made my day once again!
THANKS!
"Oxytoma Hargrovei"
Thanks, "hschlauch"! Your posts often remind me of that old "Management Guru," Tom Peters. He was famous for saying...."There are no excellent companies!" What he meant was....there's no perfect company and top management must always be re-imagining what their product is and what the best version of their product can be. I hope that some ONCS top brass get a chance to tune into this Board and see some of the thoughts expressed about the "micro" environment of their present trials. I think you supply a lot of "re-imagination" food for thought that ONCS senior scientists might want to compile and, at least, consider as the appropriate timeframe and resources permit. The ONCS story is a long way from completion and it's very possible that, if they do continuously "re-imagine" what their BEST product can be, the Company might outlive many of the lives they're on track to help and cure! It's thinking like yours, "hschlauch," that might just help ONCS "re-imagine" what its BEST product can be!
"OXYTOMA HARGROVEI"
"hschlauch,"
In your post #45673, you conclude with....."Based on prior observations, the reported PISCES patients will more than likely see deepening responses over time. Just my opinion." Well, there are many on this board who don't have the vast "microbiology" background you apparently possess. So, your opinions
are very meaningful to all of us. Your most recent post goes into a lot of details about Tregs, CTLA-4, CD28 T cells as well as CD80 & CD86 cells, and the release of tumor antigens, and more. Do you think the "geniuses" at ONCS are addressing the most important factors/impact of these "Micro" features to get the maximum results in the current PISCES Trial? In your opinion, do you think they could be missing some very important elements to trial success? Maybe, that's too much to ask but "your opinion" is BIG on this Board.
Glad to hear your wife had such an excellent outcome with her pregnancy and if your child has your inquisitive mind and spirit, I believe you must have an exciting household most of the time! Lucky child!
"OXYTOMA HARGROVEI"
Along with many other "Board Members," I certainly agree with your remark about "hschlauch!" In fact, my recent "irrational exuberance" about the coming trial data seems to be creeping back into my thinking.....I say that with a big smile on my face! A"toast" to "hschlauch" for his contributions to our "BOARD!" MANY THANKS TO HIM!
"OXYTOMA HARGROVEI"
IN "HSCHLAUCH" WE TRUST!
"hschlauch," you're right.....I got too excited about what I thought could be a bigger, detailed presentation
on the data coming out later in November/December!
Thanks for leading me in the right direction again....."Irrational exuberance!" got me carried away!
I'm grounded once again! THANKS!
Still,
"OXYTOMA HARGROVEI"
Click on jondoeuk's reference (msg. #45481) and see what you think.....also, read recent "board
messages" related to the conference coming up at the end of November! Lots of DD on Oncosec can
be seen at the iHub site highlighting "ONCS."
Best wishes!
"OXYTOMA HARGROVEI"
HMMMMMMMMM.......is this a "Cat out of the bag!" headline or something that has been expected based on recent announcements/articles.......seems to be more than just a "suspected" outcome based on some observations made by "informed" members of this board! "Algazi" is a noted ONCOSEC associate who not only knows what he's talking about but does the the "investigated research" to back up the data/info he presents!
"OXYTOMA HARGROVEI"
"hschlauch," thanks for your insightful perspective about the referenced publication...... "Obviously, just like everything else in immunology, the observations would need to translate into humans. But if it does, it could potentially negate the need for systemic anti-pd-1 agents!"
WOW! If that would turn out to be the case, a "thunderous rush" by Big Pharma would head in ONCOSEC'S direction at "light speed" to partner-up or buy them up! What a development that would be!
THANKS, as always, for your astute observations!
Still,
"OXYTOMA HARGROVEI"
Anytime I see Dr. Robert H. Pierce's connection to any ONCOSEC related announcement, I read the information several times with GREAT interest. He's a "medical expert" with a renowned reputation! I'm not the only one following his trail for the promise of successful cancer treatment for some of the most
dangerous, hard-to-treat forms of this disease.......I wish him continued success in his medical pursuits!
A MAJOR TIP OF THE HAT TO DR. ROBERT H. PIERCE!
"Oxytoma Hargrovei"
Dr. Pierce - - - -> Dr. Algazi!
Quite a tribute to OncoSec's unique medical achievements through trial results to date and breakthrough therapies on the horizon! Both of those two immensely gifted,"medical virtuoso-calibre" researchers will one day take their place in the "MEDICAL HALL OF FAME!"
We will all be very proud that we had a ring-side seat to their contributions to OncoSec and the greater medical community!
Great news today!
Great posts "Wait" & "Trading.Jeff"......I can't remember who said, "I love it when a plan comes together!" After reading your posts that's what came to mind....Good grief! Did they used to say that on
episodes of the "A-Team"?!?! Oh well, if the shoe fits, wear it! I've got my boots on!
ONCS looking Good!
THANKS! May "The Force" be with all of us here on the ONCS Board!
Good week so far!
Perhaps, I was being impolite.....did not mean to be so.....dangerM, you are an important resource for this Board and a truly valuable contributor to its informative discussion base. I didn't mean to question that at all. Others, including "hschlauch," have often commented on important Board info sharing. That was my purpose here.
Best wishes to you always,
"Oxytoma Hargrovei!"
If Dr. Pierce is not available to provide his take on this very interesting post, I'm hoping "hschlauch" might be available for some comment. This seems to be part of a very interesting, unfolding set of clues relating to ONCS' future plasmid combinations. More is better as far as comments are concerned!
THANKS!
"The Three Stock-a-teers," Chickpea598, Trading.jeff, & Waitforit53, all reporting in with great info/comments this morning.......it's like hitting a "trifecta" at the race track! Nice way to start the day!
Best wake-up-call I've had this week!
Keep the pot boiling until ONCS charges out of the gate!
Have a great day!
THANKS!
Thanks chickpea598 and trading.jeff for your thoughtful, valid comments....I'm paying attention and learning a lot!
ONCS ready to leave the station!
All aboard!
I've got my ticket!
On 12/27/17 "hschlauch" posted the following:
" I really do believe this first multi gene construct is going to be disruptive. The single issue I have with Immunopulse IL-12 is that it doesn't address overcoming the initial stages of immune suppression. That is, having too many Tregs at the start of an immune response isn't a good thing. Obviously, this isn't a problem for perhaps the majority of patients as we have seen remarkable complete responses so far. However, for those patients who haven't responded to the combination of Immunopulse IL-12 and Keytruda, it seems to be clear that they aren't activating enough CTL. I attribute this to too many intratumoral Tregs expressing CTLA-4.
I think this first PIIM construct will allow for APCs, like dendritic cells, to numerically overwhelm Tregs and their associated CTLA-4-derived suppressor effects. In theory, you may not actually need an anti-CTLA-4 agent. This new multi gene construct should lead to improvements in CD8 T cell activation and proliferation. I am actually so optimistic that I think it will convert nearly all anti-PD-1 nonresponders into responders, not just in metastatic melanoma but also in many other solid tumor cancers."
"hschlauch", thanks for just giving us the latest on the implications for ONCS' future regarding their first
PIIM Construct.......we don't have to look to far over the horizon to see a "BIG" success story unfolding for ONCS! We heard it here first!
THANKS!
New large and increased stock purchases of ONCS are not made based on willy, nilly expectations of
performance. There is a lot of trust being displayed in the anticipation of BIG things on the horizon.
'
Thanks for the update "Trading Jeff!" You are on my "Pay attention to him list!"
Nice news for a HOT Friday!
Good Job!
This "hschlauch" post compliments his post of December 27, 2017 and supplements others made during 2018. He has provided us an ongoing study/story of what seems to be happening with ONCS' scientific/medical developments/achievements. Thanks for your expert perspective on what has transpired and what ONCS' future may very well look like. I'm all eyes and ears when I see you have posted. THANKS FOR YOUR KEEN INSIGHTS ON ONCS!
When I read the closing comment you made in your recent post....".I am actually so optimistic that I think it will convert nearly all anti-PD-1 nonresponders into responders, not just in metastatic melanoma but also in many other solid tumor cancers".....I thought of a line from the classic Western Movie, "Butch
Cassidy and the Sundance Kid" where Sundance turns to Butch Cassidy and says, "Butch, you just keep on thinking because that's what you're good at!" Compliment to you - - - -> In addition to channelling
Dr. Pierce, I do think you are this Board's "Butch Cassidy!" When ONCS' PIIM construct bursts onto the biotechnology scene, I'm going to come back to your latest post and just look at it for a long time and reflect on "How did "hschlauch" know this was coming?" Looks like a banner year for ONCS in 2018!
Happy New Year, "hschlauch!" And, I hope you will just keep on thinking about what's going on with the medical/scientific advances being made by ONCS because you are really good at doing that! THANKS!!!!!!!!
"hschlauch," with another informative article about OncoSec's multigene combination possibilities! If OncoSec comes through with a successful mulitigene combination in 2018, "Figure 1" in the referenced article could be modified to show an "electroporation device with an injection apparatus!" instead of the syringe! I wouldn't be surprised to see that development in 2018. Thanks, "hschlauch," for a adding an extra smile to my Holiday Season! Hope yours is full of smiles and joy!
Great news from Wait.....excellent way for ONCS to keep its "finger on the pulse" regarding the latest developments in the commercial biotechnology field....O'Connor showing his value to ONCS by participation on the New Jersey Board.
Side Bar Note......."hschlauch," like Dr. Pierce, has an in-depth knowledge of "cell biology/dynamics."
That's the reason we should pay very close attention to what he has to say on this board. There are many others who have lots to offer too, including Wait. I thank them all!
Wait......'tis the season of smiles and joy.......thank-you for adding a smile to my day! My mom told me when I was a little kid that nobody can erase a smile......THANKS! I'm still smiling!!!!!!!!!!!!!!!!!
Wait.....I laughed out loud when I read your post.....I guess we both love it when Dr. Pierce "talks dirty"
too! Thanks for your informative posts and you know how to sprinkle some "good humor' among them.
That's a noble talent! THANKS!
Sometimes I think "hschlauch" is a "pseudonym" for Dr. Pierce! Anybody ever seen "hschlauch" and "Dr. Pierce" in the same place at the same time? This is something I think about most often when there is a full moon......anybody else having the same thought?
Not sure what we'd do without "hschlauch" and his enlightening posts!?!?
Keep those good vibes flowing!
THANKS!
Don't forget that Merck is interested in Animal Health and cancer cures for canines! So, ONCS is going to the dogs too......"OncoSec Medical and UC Davis School of Veterinary Medicine Collaborate to Test Intratumoral Cancer Immunotherapy in Canine Soft Tissue Sarcoma"
Jun 01, 2015, 06:00 ET from OncoSec Medical Inc.
Sometimes it's good to be going to the dogs.....Bow-wow, ONCS, Bow-wow!!!!
Is Heat Biologics a threat to ONCS. It's "vaccination approach" to immunotherapy seems to rival
the IL-12 capability of ONCS. Heat had a successful collaboration with ONCS' electroporation device being used. Heat also has reported good results in combination with Opdivo (Bristol Myers). Are Heat and ONCS in some kind of race to the finish line where the "Winner!" gets the lion's share of BIG PHARMA'S collaboration $$$$$$$$?
CURIOUS GEORGE